Angiotensin-converting enzyme inhibitors and angioedema: Estimating the risk

Hypertension

Volumn 51, Issue 6, 2008, Pages 1465-1467

  Weber, Michael A ^a,b   Messerli, Franz H ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMLODIPINE; ANTIHISTAMINIC AGENT; ATENOLOL; BRADYKININ; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; LOSARTAN; OMAPATRILAT; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; CLINICAL PRACTICE; COUGHING; DIAGNOSTIC ACCURACY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; INCIDENCE; INTUBATION; PRIORITY JOURNAL; PROBABILITY; RASH; RESPIRATORY DISTRESS; TRACHEOSTOMY; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; NOTE; RISK FACTOR;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; INCIDENCE; RISK FACTORS;

EID: 45849088780     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.111393     Document Type: Editorial

References (11)

1. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609.
2. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfield DE. Angioedema incidence in US veterans initiating angiotensin- converting enzyme inhibitors. Hypertension. 2008;51:1624-1630.
3. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
4. Tojo A, Onozato ML, Fujita T. Repeated subileus due to angioedema during renin-angiotensin system blockade. Am J Med Sci. 2006;332:36-38.
5. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci. 2001;46:1239-1243.
6. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Herbert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
7. Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL. ALLHAT Collaborative Research Group. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attach Trial (ALLHAT). J Clin Hypertens. 2006;8:649-656.
8. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, Levy E. Incidence and characteristics of angioedema associated with enalapril. Arch Int Med. 2005;165:1637-1642.
9. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, Cicardi M. Angioedema without urticaria: a large clinical survey. CMAJ. 2006;175:1065-1070.
10. Julius S, Kjeldsen SE, Weber MA, Brunner HR, Ekman S, Hansson L,Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
11. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.